Patents by Inventor John F. Traverse

John F. Traverse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Processes for the preparation of ()-tert-butyl 4,5-diamino-5-oxopentanoate
    Patent number: 11912644
    Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: February 27, 2024
    Assignee: Celgene Corporation
    Inventors: John F. Traverse, Michael J. Zacuto, Weihong Zhang, Kirsten Faye Johnson, Maryll E. Geherty, Christopher Marton
  • PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE
    Publication number: 20230234914
    Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.
    Type: Application
    Filed: November 1, 2022
    Publication date: July 27, 2023
    Inventors: John F. Traverse, Michael J. Zacuto, Weihong Zhang, Kirsten Faye Johnson, Maryll E. Geherty, Christopher Marton
  • MK2 inhibitors, synthesis thereof, and intermediates thereto
    Patent number: 11655257
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: May 23, 2023
    Assignee: Celgene CAR LLC
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, Jr., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • Processes for the preparation of (S)-tert-butyl 4,5- diamino-5-oxopentanoate
    Patent number: 11505522
    Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: November 22, 2022
    Assignee: CELGENE CORPORATION
    Inventors: John F. Traverse, Michael J. Zacuto, Weihong Zhang, Kirsten Faye Johnson, Maryll E. Geherty, Christopher Marton
  • SALTS AND SOLID FORMS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
    Publication number: 20220125797
    Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Inventors: Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
  • Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
    Patent number: 11241439
    Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: February 8, 2022
    Assignee: Celgene Corporation
    Inventors: Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
  • MK2 INHIBITORS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
    Publication number: 20210139501
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 13, 2021
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, JR., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • MK2 inhibitors, synthesis thereof, and intermediates thereto
    Patent number: 10894796
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: January 19, 2021
    Assignee: Celgene CAR LLC
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, Jr., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • SALTS AND SOLID FORMS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
    Publication number: 20200360395
    Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
    Type: Application
    Filed: February 25, 2020
    Publication date: November 19, 2020
    Inventors: Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
  • ISOTOPOLOGUES OF 5-AZACYTIDINE
    Publication number: 20200316099
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 8, 2020
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE
    Publication number: 20200299228
    Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.
    Type: Application
    Filed: June 5, 2020
    Publication date: September 24, 2020
    Inventors: John F. Traverse, Michael J. Zacuto, Weihong Zhang, Kirsten Faye Johnson, Maryll E. Geherty, Christopher Marton
  • Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate
    Patent number: 10717703
    Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: July 21, 2020
    Assignee: Celgene Corporation
    Inventors: John F. Traverse, Michael J. Zacuto, Weihong Zhang, Kirsten Faye Johnson, Maryll E. Geherty, Christopher Marton
  • Isotopologues of 5-azacytidine
    Patent number: 10646503
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: May 12, 2020
    Assignee: Celgene Corporation
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • MK2 INHIBITORS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
    Publication number: 20200102326
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Application
    Filed: March 15, 2018
    Publication date: April 2, 2020
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, JR., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • ISOTOPOLOGUES OF 5-AZACYTIDINE
    Publication number: 20200101095
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: September 25, 2019
    Publication date: April 2, 2020
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl) oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
    Patent number: 10596180
    Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: March 24, 2020
    Assignee: Celgene Corporation
    Inventors: Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
  • SALTS AND SOLID FORMS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
    Publication number: 20190365772
    Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 5, 2019
    Inventors: Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
  • Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
    Patent number: 10463672
    Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: November 5, 2019
    Assignee: Celgene Corporation
    Inventors: Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
  • Isotopologues of 5-azacytidine
    Patent number: 10463683
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: November 5, 2019
    Assignee: Celgene Corporation
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • ISOTOPOLOGUES OF 5-AZACYTIDINE
    Publication number: 20190231803
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: January 9, 2019
    Publication date: August 1, 2019
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom